<DOC>
	<DOCNO>NCT03055767</DOCNO>
	<brief_summary>The purpose research examine outcomes pediatric patient receive Botulinum toxin type A ( Botox ® ) treatment migraine . There limited literature effectiveness Botox ® treatment chronic neurological pain pediatric patient , specifically treatment migraine .</brief_summary>
	<brief_title>Effectiveness Onabotulinumtoxin A ( Botox ) Pediatric Patients Experiencing Migraines : A Study Pediatric Pain Population</brief_title>
	<detailed_description>Medical Literature approximate one three child experience chronic headache lifetime , increase child reach adolescence . Migraines make nearly 60 % visit pediatric headache specialist . Studies demonstrate negative impact childhood migraine overall quality life similar pediatric cancer , heart disease rheumatic disease . As frequency migraine attack increase , proportionally child 's disability lose school time family social interaction , may lead turn economic disability . Studies estimate health care cost 70 % high family migraine non-migraine affected family , direct medical cost child migraine report similar adult . A study publish JAMA 2003 find health care cost , work-related disability parent lose educational opportunity child lead annual economic impact US approximately $ 36 billion due direct medical cost lose productivity adulthood . Onaboutlinum ( BOTOX ) currently FDA approve successful treatment prevent migraine adult , however yet child . Current treatment migraine child appear insufficient . No trial currently exist literature prospectively study onabotulinumtoxinA efficacy and/or safety indication pediatric migraine , although significant contribution make retrospective case series last 10 year . This research first investigator-initiated study study BOTOX ( R ) child prospectively randomize control placebo , cross-over study . The override rationale demonstrate efficacy , tolerability safety onabotulinumtoxinA pediatric migraine thereby potentially hasten lengthy process evaluate BOTOX® approval pediatric population .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Children age 8 17 year age history migraine meeting criterion establish ICHDII ( 2004 ) , Section 1 . Patients provide least 28day baseline data form daily diary must least 15 day report headache period , least 4 distinct episode last least 4 hour . Previous use botulinum toxin serotype reason Pregnancy . Diagnosis Myasthenia gravis , Eaton Lambert Syndrome , Amyotrophic Lateral Sclerosis Treatment headache use acupuncture , transcutaneous electrical stimulation ( TENS ) , cranial traction , dental splint , injection anesthetics/steroids within 4 week prior week screen visit</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>